Bromocriptine in Parkinsonism.
Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa. Neurological deficits improved by almost 20% in severely disabled patients; amelioration of mildly affected patients was about 10%. Adverse reactions were similar to those encountered with levodopa-they were all dose-dependent and reversible. These observations are discussed in relation to certain theoretical advantages which might be expected from a drug which acts directly on dopaminergic receptors.
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001966:Bromine / Q000627:therapeutic use; D004298:Dopamine; D004305:Dose-Response Relationship, Drug; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011674:Pulse / Q000187:drug effects; D011955:Receptors, Drug
D004876:Ergot Alkaloids; D011955:Receptors, Drug; D007980:Levodopa; D001966:Bromine; D004298:Dopamine